A Retrospective Chart Review Study of the Outcomes of 2nd Line Therapy With LEn/Dex in Greek Patients With R/R Multiple MyEloma and the Treatment PatterNs Following Progressive Disease

Inclusion Criteria: Subjects must fulfill ALL of the following criteria: * Subjects of both genders, aged 18 years or older * Subjects must have a relapsed or refractory MM diagnosis according to IMWG or EBMT criteria * Subjects must have initiated second-line therapy with lenalidomide/dexamethasone according to the approved products' Summary of Product Characteristics (SmPC) between 01 January 2009 and 01 March 2014 * Subjects must have available medical files/records and detailed historical data on their disease course and clinical management * Provision of signed ICF for collecting and analyzing medical data pertinent to the objectives of this study Exclusion Criteria: For the candidate subjects NONE of the following criteria should apply: * Prior malignancy (within the 3 years preceding initial diagnosis of MM) * Concurrent administration of anti-cancer regimens for malignancies other than MM between the time of initial MM diagnosis and time of second relapse * Subject participation in an interventional study